How SNAC Makes Oral Semaglutide Possible
Oral Peptide Delivery
0.4-1% bioavailability
Oral semaglutide achieves less than 1% bioavailability, yet this is enough for clinical efficacy thanks to SNAC's triple mechanism of action.
Buckley et al., Science Translational Medicine, 2018
Buckley et al., Science Translational Medicine, 2018
View as imageMost peptide drugs cannot survive the stomach. Gastric acid destroys them, pepsin shreds them, and the gut lining blocks whatever fragments remain from reaching the bloodstream. Oral semaglutide (Rybelsus) broke through this barrier in 2019, becoming the first oral GLP-1 receptor agonist approved by the FDA. The key was not semaglutide itself but its co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a small fatty acid derivative that solves three problems simultaneously: it buffers local stomach pH, promotes semaglutide monomerization, and increases gastric epithelial membrane permeability.[1] For a broader look at the pipeline of oral peptide drugs in development, see our pillar article on oral peptide delivery.
Key Takeaways
- SNAC enables oral semaglutide absorption in the stomach, not the intestine, as confirmed by scintigraphic imaging in humans (Buckley et al., 2018)
- Oral semaglutide achieves 0.4-1% bioavailability, enough for clinical efficacy at the 14 mg dose with 300 mg SNAC (Ariaee et al., 2026)
- SNAC works through three simultaneous mechanisms: local pH buffering that inactivates pepsin, promotion of semaglutide monomerization, and increased membrane fluidity for transcellular passage (Lewis et al., 2022)
- A 2025 Nature Communications study identified the molecular mechanism: SNAC creates transient membrane defects that allow large polar peptides to cross the epithelium (Colston et al., 2025)
- The PIONEER clinical trial program demonstrated oral semaglutide's efficacy across 10+ phase 3 trials with over 9,000 patients (Aroda et al., 2023)
The Problem SNAC Solves
Peptides face three barriers to oral delivery. First, gastric acid (pH 1-3) denatures their tertiary structure. Second, digestive enzymes, primarily pepsin in the stomach and pancreatic proteases in the intestine, cleave peptide bonds. Third, the gastrointestinal epithelium presents a physical barrier that large, charged molecules cannot cross passively.[2] These barriers are why you cannot simply swallow most peptides and expect a therapeutic effect.
Semaglutide is a 31-amino-acid GLP-1 analog with a molecular weight of approximately 4,114 Da. Like other peptide GLP-1 receptor agonists, it was originally developed as an injectable (Ozempic, approved 2017). The development of an oral formulation required solving all three barriers simultaneously, which is where SNAC enters the picture.
SNAC (also called salcaprozate sodium) is a synthetic derivative of salicylic acid linked to a medium-chain fatty acid. It has Generally Recognized as Safe (GRAS) status from the FDA and was previously approved as a medical food (Eligen B12) for enhancing vitamin B12 absorption.[3] Its application to semaglutide delivery, however, was a leap in complexity: moving from a small vitamin to a 4 kDa peptide.
Three Mechanisms Working Together
pH Buffering: Shutting Down Pepsin
When a Rybelsus tablet reaches the stomach, it erodes rapidly, releasing 300 mg of SNAC. This creates a localized zone of elevated pH around the dissolving tablet.[1] The pH increase matters because pepsin, the primary gastric protease, is most active at pH 1.5-2.5 and is largely inactive above pH 5. By buffering the local environment, SNAC reduces the conversion of pepsinogen to active pepsin and slows the enzymatic degradation of semaglutide during the critical absorption window.
This is a localized effect, not a systemic change in gastric pH. The bulk stomach acid remains acidic; only the immediate vicinity of the tablet is buffered. This localization is one reason the Rybelsus dosing instructions require taking the tablet with no more than 120 ml of water on an empty stomach: excess water would dilute the SNAC concentration and reduce its pH-buffering capacity.[4]
Monomerization: Breaking Up Peptide Clumps
Semaglutide, like many lipidated peptides, tends to self-associate into oligomers in aqueous solution. The fatty acid side chain (a C18 fatty diacid) that gives semaglutide its long half-life also promotes hydrophobic interactions between molecules. Oligomeric semaglutide is too large to cross the gastric epithelium.
SNAC addresses this by changing the local polarity of the solution as the tablet dissolves, weakening the hydrophobic interactions that drive oligomerization.[1] Twarog et al. (2022) characterized the physicochemical interactions between semaglutide-related peptides and SNAC, finding that SNAC disrupts peptide aggregation more effectively than sodium caprate (C10), the other major permeation enhancer used in oral peptide formulations.[5] The monomeric form is both smaller and more amenable to transcellular passage.
Membrane Permeability: Opening the Gate
The third and most mechanistically complex function of SNAC is increasing the permeability of the gastric epithelium. SNAC interacts with and fluidizes lipid membranes, increasing their permeability and enhancing transcellular passage of semaglutide.[1] This is distinct from paracellular transport (between cells via tight junctions): SNAC drives absorption through the cells themselves.
Colston et al. (2025) published in Nature Communications the first molecular-level explanation of how permeation enhancers like SNAC create passage for large polar peptides through cell membranes.[6] Using molecular dynamics simulations, they showed that SNAC induces transient defects in the lipid bilayer. These defects are large enough for monomeric semaglutide to pass through but close rapidly after the peptide transits, preserving overall membrane integrity. This "transient defect" model explains why SNAC enhances absorption without causing lasting damage to the gastric lining.
Tran et al. (2024) tested SNAC erodible tablets for gastric delivery of a dual GIP/GLP-1 peptide in monkeys, confirming that SNAC's permeation enhancement extends beyond semaglutide to other peptides, though with different absorption profiles depending on the peptide's physicochemical properties.[7] This has implications for the broader development of permeation enhancers for oral peptide delivery.
Stomach, Not Intestine: Where Absorption Happens
One of the most surprising findings about oral semaglutide is that it is absorbed in the stomach, not the small intestine where most oral drugs enter the bloodstream.
Buckley et al. (2018) demonstrated this using scintigraphic imaging in human volunteers. After a single dose of oral semaglutide (10 mg semaglutide with 300 mg SNAC), gamma camera imaging tracked the tablet's dissolution and semaglutide's absorption in real time.[1] The tablet eroded in the stomach, and semaglutide was absorbed through the gastric epithelium before reaching the intestine. Plasma semaglutide levels rose while the tablet was still dissolving in the stomach, confirming transcellular gastric absorption.
This gastric route has advantages and disadvantages. The stomach has a smaller absorptive surface area than the small intestine, contributing to the low bioavailability (0.4-1%).[8] However, the stomach is a simpler environment for a permeation enhancer to work in: fewer competing digestive enzymes (mainly pepsin, versus the cocktail of pancreatic proteases in the duodenum), a more predictable transit time when the tablet is taken on an empty stomach, and a single cell type (gastric epithelium) to cross.
Agarwal et al. (2025) used pharmacokinetic modeling and molecular dynamics simulations to confirm that semaglutide's absorption is highly dependent on its conformational properties in the gastric environment. The alpha-helical structure maintained by SNAC's local environment is critical for transcellular passage.[9]
Clinical Validation: The PIONEER Program
The PIONEER clinical trial program validated oral semaglutide across more than 10 phase 3 trials enrolling over 9,000 patients with type 2 diabetes.[10]
Aroda et al. (2023) published a comprehensive safety analysis across both the SUSTAIN (subcutaneous) and PIONEER (oral) programs. Gastrointestinal events, primarily nausea, were the most common adverse effects of oral semaglutide, occurring in approximately 15-20% of patients on the 14 mg dose.[10] These events were mostly mild to moderate and occurred primarily during dose escalation. The safety profile was generally consistent between subcutaneous and oral formulations, suggesting the GI events are driven by GLP-1 receptor activation rather than by SNAC itself, though this distinction has been complicated by more recent preclinical findings (discussed below).
PIONEER 5, conducted by Mosenzon et al. (2019), specifically tested oral semaglutide in patients with type 2 diabetes and moderate renal impairment, demonstrating efficacy and safety in this higher-risk population.[11] The trial showed statistically superior HbA1c reduction versus placebo at 26 weeks, confirming that SNAC-enabled oral delivery achieves therapeutically meaningful drug levels even in patients with complicating conditions. This was a meaningful test of the SNAC platform because renal impairment can alter gastric motility and pH, both of which affect SNAC's mechanism.
Dosing Conditions and Pharmacokinetic Sensitivity
Won et al. (2025) reviewed the early-phase clinical pharmacology data and noted that oral semaglutide's bioavailability was sensitive to dosing conditions: fasting state, water volume, and post-dose fasting duration all influenced absorption.[4] Bioavailability increased with longer post-dose fasting times, reaching a plateau of approximately 1.4% at 120 minutes, and decreased with water volumes above 120 ml. These strict dosing requirements are a direct consequence of SNAC's localized mechanism: anything that dilutes or displaces the SNAC-semaglutide solution from the gastric epithelium reduces absorption.
The dose escalation protocol (3 mg for 30 days, then 7 mg for 30 days, then 14 mg) was designed partly around SNAC's absorption characteristics. The low starting dose with gradual escalation allows GI adaptation while the steady-state pharmacokinetics of SNAC-enabled absorption stabilize. Lewis et al. (2022) noted that achieving consistent plasma levels required careful optimization of the tablet erosion rate to match the kinetics of SNAC's pH buffering and permeation enhancement effects.[3] For context on how semaglutide works once it reaches the bloodstream, our weight loss data article covers the clinical outcomes.
SNAC vs. Other Permeation Enhancers
SNAC is not the only permeation enhancer studied for oral peptide delivery. Sodium caprate (C10) has a longer research history and works primarily in the intestine rather than the stomach.
Twarog et al. (2022) directly compared SNAC and C10 and found key differences in their interaction mechanisms.[5] SNAC forms non-covalent complexes with peptides, increasing their lipophilicity and promoting transcellular passage. C10 acts more broadly on membrane permeability but works in the intestine, where the enzymatic environment is harsher. Bardonnet et al. (2025) showed that C10-based formulations face challenges from low gastric pH that SNAC's buffering capacity avoids.[12]
The practical difference: SNAC co-formulated with semaglutide achieved FDA approval as Rybelsus. No C10-based oral peptide formulation has reached the market, though several are in clinical trials for other peptides.
Beyond enhancer chemistry, the site of absorption matters. SNAC targets the stomach, where the single-cell-type epithelium and relatively simple enzymatic environment (pepsin only) create a more predictable absorption window. C10-based approaches target the small intestine, where the absorptive surface area is vastly larger but the enzymatic gauntlet (trypsin, chymotrypsin, carboxypeptidases, aminopeptidases) is far more destructive to peptides. Each approach involves trade-offs between absorption efficiency and peptide survival.
The success of the SNAC approach has accelerated interest in enteric coatings and enzyme inhibitor strategies as complementary technologies for oral peptide delivery. Combining SNAC with protease inhibitors or mucoadhesive polymers could theoretically increase the absorption window and bioavailability beyond the current 1% ceiling, though no such combination has reached clinical trials.
What SNAC Does Not Solve
SNAC made oral semaglutide possible, but the technology has clear limitations.
Low bioavailability. Even with SNAC's triple mechanism, oral semaglutide achieves only 0.4-1% bioavailability. This means 99% of the dose is wasted. The 14 mg oral dose delivers roughly the same plasma levels as 0.5 mg subcutaneous semaglutide.[3] The cost implications are significant: oral semaglutide requires more active ingredient per effective dose.
Strict dosing requirements. The tablet must be taken on an empty stomach with no more than 120 ml of water, followed by at least 30 minutes of fasting. These restrictions reduce patient convenience, the primary advantage oral formulations are supposed to offer.
Variable absorption. Meal timing, water volume, gastric motility, and individual variations in gastric pH all affect absorption. Ke et al. (2024) noted that this pharmacokinetic variability is a fundamental challenge for oral GLP-1 receptor agonists that SNAC-based formulations have not fully resolved.[13]
GI side effects from SNAC itself. Ariaee et al. (2026) found that SNAC alters gut microbiota composition and is associated with systemic inflammation markers in animal models, raising questions about whether some of the gastrointestinal adverse events attributed to semaglutide may actually be caused by the SNAC excipient.[8] This finding is preliminary but relevant for next-generation formulations.
Peptide-specific. SNAC's effectiveness depends on the physicochemical properties of the co-formulated peptide. Tran et al. (2024) showed that while SNAC enhanced gastric absorption of a GIP/GLP-1 dual agonist in monkeys, the absorption profile differed from semaglutide, suggesting each new peptide-SNAC combination requires independent optimization.[7]
Madny et al. (2026) placed these limitations in the broader context of the venom-to-vial-to-pill journey of GLP-1 peptides, noting that biopharmaceutics modeling is increasingly critical for predicting which peptide-enhancer combinations will achieve clinically useful bioavailability.[14] The complete GLP-1 receptor agonist class comparison shows how oral semaglutide fits within the broader therapeutic landscape.
The Bottom Line
SNAC enables oral semaglutide by solving three problems simultaneously: buffering local stomach pH to inactivate pepsin, promoting semaglutide monomerization for transcellular passage, and creating transient membrane defects that allow the peptide to cross the gastric epithelium. The result is a 0.4-1% bioavailability that, despite being low, delivers clinically meaningful GLP-1 receptor activation. SNAC's limitations, including strict dosing requirements, absorption variability, and potential GI effects from the enhancer itself, define the challenges for next-generation oral peptide formulations.